Protexa Therapeutics Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Protexa Therapeutics General Information
Description
Developer of proprietary pharmaceutical products based on a platform of TGF-beta production stimulators. The company's lead product is a proprietary fixed-dose combination of droloxifene and clopidogrel, being developed for the treatment of cardiovascular disease, and in particular acute coronary syndromes.
Contact Information
Formerly Known As
Johns Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 9 St Johns Street
- Cambridgeshire
- Duxford CB22 4RA
- England, United Kingdom
Protexa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 01-Jan-2012 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Startup |
Protexa Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Total Medical Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |